US 12,084,727 B2
Microbiome markers and therapies for autism spectrum disorders
Rosa Krajmalnik-Brown, Chandler, AZ (US); Dae-Wook Kang, Phoenix, AZ (US); Jin Gyoon Park, Phoenix, AZ (US); Joshua Labaer, Chandler, AZ (US); and Zehra IIhan, Tempe, AZ (US)
Assigned to Arizona Board of Regents on Behalf of Arizona State University, Tempe, AZ (US)
Filed by Arizona Board of Regents on Behalf of Arizona State University, Tempe, AZ (US)
Filed on Dec. 28, 2022, as Appl. No. 18/147,224.
Application 15/629,962 is a division of application No. 14/403,425, granted, now 9,719,144, issued on Aug. 1, 2017, previously published as PCT/US2013/032668, filed on Mar. 15, 2013.
Application 18/147,224 is a continuation of application No. 16/118,061, filed on Aug. 30, 2018, granted, now 11,542,560.
Application 16/118,061 is a continuation of application No. 15/629,962, filed on Jun. 22, 2017, abandoned.
Claims priority of provisional application 61/651,846, filed on May 25, 2012.
Prior Publication US 2023/0220494 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/689 (2018.01); A61K 31/437 (2006.01); A61K 35/741 (2015.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)
CPC C12Q 1/689 (2013.01) [A61K 31/437 (2013.01); A61K 35/741 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6896 (2013.01); C12Q 2600/142 (2013.01); C12Q 2600/158 (2013.01)] 9 Claims
 
1. A method of treating Autism Spectrum Disorder in a human subject in need thereof, comprising:
a. determining or having determined abundance of a bacteria in the genus Prevotella in a fecal microbiota obtained from the subject;
b. identifying the subject as having Autism Spectrum Disorder if the subject is determined to have a lower relative abundance of Prevotella copri or Prevotella paludivivens compared to a neurotypical person; and
c. administering to the subject a pharmaceutical composition comprising a probiotic that modulates the abundance of the bacteria in the genus Prevotella in the subject's fecal microbiota.